Chapter 33 Nursing School Test Banks

 

1.

When planning care for a patient who is receiving filgrastim (Neupogen) for a nonmyeloid malignancy, the nurse will formulate which of the following patient outcomes? (Select all that apply.)

A)

The patient will not develop an infection.

B)

The patient will not experience bone pain.

C)

The patient will be able to self-administer filgrastim at home.

D)

The patient will not develop febrile neutropenia.

E)

The patient will not retain fluid.

2.

A nurse is to administer 0.5 mL of epoetin alfa to a 39-year-old woman who is being treated for chemotherapy-induced anemia. She will use a single-dose 1-mL vial. Which of the following will the nurse do with the unused portion of the drug?

A)

Refrigerate the medication for a future use.

B)

Discard the unused portion of the drug.

C)

Store the medication in the drug cart for the next dose.

D)

Put the medication in the freezer compartment of the refrigerator.

3.

A female patient is prescribed oprelvekin therapy to treat thrombocytopenia. Which of the following should the nurse continuously monitor to determine the efficacy and duration of the oprelvekin therapy?

A)

Weight gain

B)

Platelet count

C)

Red and white blood cell count

D)

Cardiac arrhythmias

4.

A female patient is taking filgrastim (Neupogen) to decrease the incidence of infection. The nurse notices a small increase in the neutrophil count 2 days after starting therapy. The nurses evaluation of the increase is that:

A)

The therapeutic effect of the drug is slow, and it is likely to cause adverse effects.

B)

The drug therapy is proving to be ineffective.

C)

The therapeutic effect of the drug is fully evident.

D)

The increase in the neutrophil count is only transient.

5.

A nurse has been assigned to a 43-year-old man who is to receive epoetin alfa therapy. The patient is HIV-positive and has anemia related to zidovudine therapy. The nurse will monitor which of the following?

A)

Iron levels

B)

Chemotherapy

C)

Renal failure

D)

Swelling of veins

6.

Which of the following patients will be at greatest risk for anemia and would be the most likely candidate for epoetin alfa therapy?

A)

A 20-year-old female

B)

A 30-year-old pregnant woman

C)

A 62-year-old male with cancer

D)

A 40-year-old male with a high white blood cell count

7.

A nurse has been assigned to a female patient who is to begin chemotherapy. The nurse will initiate the prescribed oprelvekin therapy:

A)

6 to 24 hours after chemotherapy

B)

2 days after chemotherapy

C)

6 days after chemotherapy

D)

10 days after chemotherapy

8.

A 67-year-old man being treated for prostate cancer is taking epoetin alfa. The nurse will instruct the patient to:

A)

Stop taking the drug after a 2-week period.

B)

Schedule an appointment to measure hematocrit twice a week for at least 2 to 6 weeks.

C)

Schedule an appointment to check if the patient has a high WBC count.

D)

Begin taking a calcium channel blocker to treat hypertension, which usually develops as an adverse effect of epoetin alfa therapy.

9.

A nurse is discussing oprelvekin therapy with a male patient. Which of the following will the nurse tell the patient is the most common adverse effect of the drug?

A)

Medullary bone pain

B)

Papilledema

C)

Fluid retention/weight gain

D)

Atrial arrhythmia

10.

A nurse is assigned to administer filgrastim to a diverse group of patients. Which of the following patients will the nurse observe for extremely elevated white blood cell counts following administration of the drug?

A)

A 19-year-old male receiving radiotherapy

B)

A 25-year-old female with a diagnosis of congenital neutropenia

C)

A 39-year-old female with a nonmyeloid malignancy

D)

A 47-year-old male with aplastic anemia

Answer Key

1.

A, B, C, D

2.

B

3.

B

4.

D

5.

A

6.

C

7.

A

8.

B

9.

C

10.

A

Page 1

Leave a Reply